Stereotaxis Projects $3M Synchrony Revenue, Readies MAGiC PFA Launch in Europe
Stereotaxis sold a single GenesisX system in 2025 and saw limited MAGiC catheter revenue due to manufacturing constraints, hindering growth. It expects FDA clearance for its $150,000-$200,000 Synchrony digital surgery suite with over $3 million in initial sales and plans Europe launch of MAGiC with Pulse Field Ablation.
1. Q4 System Sales and Catheter Challenges
In 2025 Stereotaxis sold only one GenesisX system and generated minimal revenue from its MAGiC and MAGiC Sweep catheters as it shifts away from third-party devices. Manufacturing capacity constraints for the proprietary MAGiC catheter have limited commercial adoption and slowed overall revenue growth.
2. Synchrony Suite Projections
The company is investing in its Synchrony digital surgery suite, expecting FDA clearance this year. With pricing set between $150,000 and $200,000 per system, management forecasts more than $3 million in initial capital sales, driven by multisystem deals and individual hospital trials.
3. MAGiC PFA Europe Launch Plan
Stereotaxis plans to introduce MAGiC with Pulse Field Ablation in Europe by year-end. Compatibility testing with existing Centauri generators has shown no significant risk, and a dossier has been submitted for review by a EU-notified body to secure regulatory approval.
4. Shift to Flexible Commercial Model
The company is transitioning to a blend of outright sales, leases and placements funded by disposable commitments, aiming to establish five GenesisX programs. Management believes this model will boost recurring revenues and enhance long-term profitability across key opinion leader accounts in the US and Europe.